Page 231 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 231

                                • Y.W.S. Jauw, J.M. Zijlstra, O.S. Hoekstra, S. Zweegman, G.A.M.S. van Dongen, M.C. Huisman. Impact of injected dose on accuracy and precision of tumor and organ uptake quantification of 89Zr-labeled anti-CD20 antibodies with PET. Poster presentation. Society of Nuclear Medicine & Molecular Imaging Annual Meeting, San Diego, USA, 2016.
• Y.W.S. Jauw, M.C. Huisman, G.A.M.S. van Dongen, J.A.J. Janssen, O.S. Hoekstra, S. Zweegman, J.M. Zijlstra. Immuno-PET in relapsed/refractory diffuse large B cell lymphoma: tumor uptake of 89Zr-rituximab. Oral presentation. Dutch Hematology Congress, Papendal, the Netherlands, 2016.
• Y.W.S. Jauw, M.C. Huisman, G.A.M.S. van Dongen, O.S. Hoekstra, J.M. Zijlstra. Biodistribution and uptake of 89Zr-rituximab and 89Zr-ofatumumab in patients with relapsed diffuse large B cell lymphoma. Poster presentation. 5th International Workshop on PET in Lymphoma, Menton, France, 2014.
List of publications
A
A
  229




























































































   229   230   231   232   233